SK Life Science (United States)

A patenting perspective of IKZF2 molecular glue degraders (2020-present)

INTRODUCTION: IKZF2 (Helios) maintains the suppressive function of regulatory T cells (Tregs) and is an emerging immuno-oncology target. Its degradation destabilizes Tregs, strengthens antitumor immunity, and may remodel the tumor microenvironment (TME) with reduced off-target to...

Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population

OBJECTIVE: This study was undertaken to assess long-term efficacy, safety, and tolerability of adjunctive cenobamate in an open-label extension (OLE) of a randomized, double-blind, placebo-controlled, dose-response study (NCT04557085; YKP3089C035 [Study C035]) in Asian patients w...